ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Eisai-Biogen Alzheimer's drug draws doubt from European regulators

Vote by European Medicines Agency panel deals setback to controversial $56,000-a-year treatment

Aduhelm, the drug U.S.-based Biogen has developed with Japan's Eisai, received a "negative trend vote" from the Committee for Medicinal Products for Human Use panel.

LONDON/NEW YORK (Financial Times) -- A key European Medicines Agency panel has signaled it is unlikely to grant approval to Biogen's drug for Alzheimer's disease, adding to the debate surrounding a controversial treatment that retails at $56,000 a year.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more